Findings from a multi-center, international clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes.
FDA grants priority review for Merck’s sNDA of renal cancer therapy
Merck filed the application based on findings from the Phase III LITESPARK-005 trial in advanced renal cell carcinoma patients. Credit: Jo Panuwat D/Shutterstock.com. The US
September 20, 2023